RxSight (RXST) Fell Due to Missed Expectations and Guidance Reduction

Core Insights - The Brown Capital Management Small Company Fund experienced an 8.59% return in Q2 2025, underperforming the Russell 2000® Growth index which returned 11.97% [1] - The underperformance was primarily noted in the last few weeks of the quarter [1] Fund Performance - Small-cap US stocks rebounded in Q2 2025 after a challenging first quarter [1] - The fund's top five holdings were highlighted as key picks for 2025 [1] Company Highlight: RxSight, Inc. - RxSight, Inc. (NASDAQ:RXST) is a commercial-stage medical device company specializing in light-adjustable intraocular lenses for cataract surgery [2] - RxSight, Inc. had a one-month return of 9.66%, but its shares have lost 83.24% of their value over the past 52 weeks [2] - As of September 12, 2025, RxSight, Inc. stock closed at $9.31 per share, with a market capitalization of $380.928 million [2] Performance Detractors - RxSight, Inc. was noted as one of the detractors to the fund's performance in Q2 2025, alongside Bio-Techne (TECH) [3]